Evidence-Based Practice Recommendations for Nutrition-Related Management of Children and Adults with Cystic Fibrosis and Pancreatic Insufficiency: Results of a Systematic Review

2008/04/27 by Virginia A. Stallings, Lori J. Stark, Karen A. Robinson +3 · 27 citations
Medicine · Nursing · #Alternative medicine #Child Nutrition and Feeding Issues #Child Nutrition and Water Access #Cystic Fibrosis Research Advances #Cystic fibrosis #Evidence-based practice #Foundation (evidence) #Intensive care medicine #Internal medicine #MEDLINE #Medicine #Pancreas #Pancreatic enzymes #Pathology #Pediatrics

paper · doi:10.1016/j.jada.2008.02.020

openalex publication_date 2008/04/27 · openalex created_date 2025/10/10 · openalex updated_date 2026/08/05

Cited by

• Unveiling the Impact of Social and Environmental Determinants of Health on Lung Function Decline in Cystic Fibrosis through Data Integration using the US Registry
• A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One F508del Allele
• Cystic Fibrosis Foundation evidence-based guidelines for management of infants with cystic fibrosis. [europepmc]
• Trends in the use of routine therapies in cystic fibrosis: 1995-2005. [europepmc]
• Impaired mucosal barrier function in the small intestine of the cystic fibrosis mouse. [europepmc]
• Progress in cystic fibrosis and the CF Therapeutics Development Network. [europepmc]
• Disrupted tight junctions in the small intestine of cystic fibrosis mice. [europepmc]
• New stable isotope method to measure protein digestibility and response to pancreatic enzyme intake in cystic fibrosis. [europepmc]
• Body composition and pulmonary function in cystic fibrosis. [europepmc]
• Medication beliefs mediate between depressive symptoms and medication adherence in cystic fibrosis. [europepmc]
• Longevity of patients with cystic fibrosis in 2000 to 2010 and beyond: survival analysis of the Cystic Fibrosis Foundation patient registry. [europepmc]
• Children and young adults with CF in the USA have better lung function compared with the UK. [europepmc]
• Early Life Growth Trajectories in Cystic Fibrosis are Associated with Pulmonary Function at Age 6 Years. [europepmc]
• Body composition and lung function in cystic fibrosis and their association with adiposity and normal-weight obesity. [europepmc]
• Background and Epidemiology. [europepmc]
• Growth in Prepubertal Children With Cystic Fibrosis Treated With Ivacaftor. [europepmc]
• Plasma metabolomics in adults with cystic fibrosis during a pulmonary exacerbation: A pilot randomized study of high-dose vitamin D 3 administration. [europepmc]
• Brazilian guidelines for the diagnosis and treatment of cystic fibrosis. [europepmc]
• Early life growth patterns persist for 12 years and impact pulmonary outcomes in cystic fibrosis. [europepmc]
• Nutritional Considerations in Pediatric Pancreatitis: A Position Paper from the NASPGHAN Pancreas Committee and ESPGHAN Cystic Fibrosis/Pancreas Working Group. [europepmc]
• Academy of Nutrition and Dietetics: 2020 Cystic Fibrosis Evidence Analysis Center Evidence-Based Nutrition Practice Guideline. [europepmc]
• Cystic Fibrosis. [europepmc]
• A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One F508del Allele. [europepmc]
• Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis: A Clinical Trial. [europepmc]
• Effect of elexacaftor-tezacaftor-ivacaftor on body weight and metabolic parameters in adults with cystic fibrosis. [europepmc]
• The Changing Landscape of Nutrition in Cystic Fibrosis: The Emergence of Overweight and Obesity. [europepmc]
• Obesity in Cystic fibrosis: prevalence, trends and associated factors data from the US cystic fibrosis foundation patient registry. [europepmc]